Latest news and press releases about Larimar Therapeutics, Inc. (LRMR): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials.
Price
| Price | $3.93 |
| Market Cap | $408M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.23 |
| EV / EBITDA | -1.85 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -137.39% |
| Return on Invested Capital | -135.25% |
| Return on Assets | -104.42% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACIU · ALT · AMRN · ANNX · ANRO · DBVT · ENGN
Explore sector: Healthcare · Biotechnology
More sections of LRMR: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks